Atossa Genetics to Present at the 15th Annual BIO CEO and Investor Conference
Presentation to Be Webcast at 1:00 pm ET on February 11, 2013
SEATTLE, WA -- (Marketwire) -- 01/28/13 -- Atossa Genetics, Inc.
(NASDAQ: ATOS), The Breast Health Company(TM), announced today that
Dr. Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President,
will present the Company's products and services at the 15th Annual
BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New
York City, on Monday, February 11, 2013, at 1:00 pm Eastern Time
(10:00 am Pacific Time). Dr. Quay's presentation will be webcast via
the Company's website at www.atossagenetics.com.
Dr. Quay stated, "The national launch of our ForeCYTE Breast Health
Test is an important achievement that positions Atossa for
accelerated growth in 2013 and beyond. I look forward to presenting
our business model, marketing plan, and additional products and
laboratory services to institutional investors at this premier event.
I believe the 2013 U.S. rollout of our ForeCYTE and ArgusCYTE Breast
Health Test, launch of the FullCYTE Breast Health Test and NextCYTE
Breast Health Test, and initiation of clinical trials for our
intraductal therapy, represent significant upside potential for
investors this year."
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company(TM),
is based in Seattle, WA, and is focused on preventing breast cancer
through the commercialization of patented, FDA-cleared diagnostic
medical devices and patented, laboratory developed tests (LDT) that
can detect precursors to breast cancer up to eight years before
mammography, and through research and development that will permit it
to commercialize treatments for pre-cancerous lesions.
The National Reference Laboratory for Breast Health (NRLBH), a wholly
owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified
high-complexity molecular diagnostic laboratory located in Seattle,
WA, that provides the patented ForeCYTE Breast Health Test, a risk
assessment test for women 18 to 73 years of age akin to the Pap
Smear, and the ArgusCYTE Breast Health Test, a blood test for
recurrence in breast cancer survivors that provides a "liquid biopsy"
for circulating cancer cells and a tailored treatment plan for
atients and their caregivers.
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding
Atossa's plans, expectations, projections, potential opportunities,
goals and objectives are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially from the anticipated or estimated future results,
including the risks and uncertainties associated with the efficacy of
Atossa's products and services, the market demand for and acceptance
of Atossa's products and services and other risks detailed from time
to time in the Atossa's final prospectus, dated November 7, 2012,
filed with the U.S. Securities and Exchange Commission. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Atossa undertakes no obligation to revise
or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release.
Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP
Chairman, President and CEO of Atossa Genetics and
Director of the National Reference Laboratory for Breast Health
w D. Haines (Investors and Media)
MBS Value Partners
Dian Griesel Inc.
Press spacebar to pause and continue. Press esc to stop.